Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection

BACKGROUND: A Phase 2a, open-label study (NCT01724086) was conducted to assess the efficacy and safety of a once-daily, 2-direct-acting-antiviral-agent (2-DAA) combination of simeprevir + TMC647055/ritonavir ± ribavirin and of the 3-DAA combination of simeprevir + TMC647055/ritonavir + JNJ-56914845...

Descripción completa

Detalles Bibliográficos
Autores principales: Bourgeois, Stefan, Van Vlierberghe, Hans, Moreno, Christophe, Orlent, Hans, Nevens, Frederik, Arastéh, Keikawus, Horsmans, Yves, Schattenberg, Jörn M., Buggisch, Peter, Francque, Sven, Vijgen, Leen, Kakuda, Thomas N., Hoeben, Eva, Luo, Donghan, Vandebosch, An, Jacquemyn, Bert, Van Remoortere, Pieter, Verloes, René
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303260/
https://www.ncbi.nlm.nih.gov/pubmed/28187751
http://dx.doi.org/10.1186/s12876-017-0580-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303260/
https://www.ncbi.nlm.nih.gov/pubmed/28187751
http://dx.doi.org/10.1186/s12876-017-0580-2

Ejemplares similares